Inventor · disambiguated record
Alexander Hird
Also filed as: HIRD ALEXANDER · HIRD ALEXANDER W
12 granted patents·14 pending applications·14 citations·filing 2006–2025
85Inventor score
Top patents by PatentIndex Score
26 records- 0195US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 0293US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 0389US9840518B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2017·Granted Dec 12, 2017·9 cites·4 claims
- 0480US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 0579US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 0679US2025127908A1Heterobifunctional conditional inhibitorsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0779US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0879US2025129070A1Bifunctional androgen receptor compoundsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0979US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1079US2025136578A1Bifunctional androgen receptor compoundsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1174US9845331B2Chemical compoundsASTRAZENECA AB·Filed 2016·Granted Dec 19, 2017·1 cites·8 claims
- 1273US2022340592A1Chemical compoundsASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 1369US11472816B2Mcl-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2020·Granted Oct 18, 2022·0 cites·9 claims
- 1468US11352369B2Pyridine and pyrimidine derivativesASTRAZENECA AB·Filed 2020·Granted Jun 7, 2022·0 cites·19 claims
- 1567US10889594B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2018·Granted Jan 12, 2021·0 cites·10 claims
- 1663US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1763US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1861US10717746B2Chemical compoundsASTRAZENECA AB·Filed 2017·Granted Jul 21, 2020·0 cites·6 claims
- 1959US10196404B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2017·Granted Feb 5, 2019·0 cites·4 claims
- 2058US2024424111A1Degrader Compounds and Uses ThereofCALICO LIFE SCIENCES LLC·Filed 2022·Application pending·0 cites
- 2158US2025302815A1Protein tyrosine phosphatase targeting ligandsCALICO LIFE SCIENCES LLC·Filed 2022·Application pending·0 cites
- 2251US2024383886A1Protein Tyrosine Phosphatase Degraders and Methods of Use ThereofCALICO LIFE SCIENCES LLC·Filed 2020·Application pending·0 cites
- 2349US11149024B2Synthesis of Mcl-1 inhibitorASTRAZENECA AB·Filed 2018·Granted Oct 19, 2021·0 cites·2 claims
- 2447US2010311748A1Heterocyclic amides useful for the treatment of cancer and psoriasisASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2541US2009275570A1Substituted heterocycles and their use as chk1, pdk1 and pak inhibitorsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 2632US2010317593A12,3-dihydro-1h-indene compoundsASTRAZENECA AB·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →